metformin has been researched along with olanzapine in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L | 1 |
| Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D | 1 |
| Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M | 1 |
| Chen, CH; Chiu, CC; Huang, MC; Liu, HC; Lu, ML; Wu, TH | 1 |
| Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP | 1 |
| Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E | 1 |
| Alamiri, B | 1 |
| Balf, G | 1 |
| Khaodhiar, L; Pramyothin, P | 1 |
| Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE | 1 |
| Case, M; Hoffmann, VP; Jacobson, JG | 1 |
| Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L | 1 |
| Asiri, Y; Barr, AM; Boyda, HN; Honer, WG; Lo, R; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C | 1 |
| Davies, GE; Davies, PS; Droke, EA; Ehli, EA; Hu, Y; Nowotny, D; Soundy, TJ; Young, AJ | 1 |
| Ahsan, Z; Chintoh, A; Giacca, A; Guenette, M; Hahn, MK; Remington, GJ; Teo, C; Wilson, V | 1 |
| Rado, J; von Ammon Cavanaugh, S | 1 |
| Nurchi, AM; Pinna, AP; Podda, F; Ripoli, C; Tronci, MG; Zanni, R | 1 |
| Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK | 1 |
| Bansal, Y; Bishnoi, M; Khare, P; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, R; Sodhi, RK | 1 |
| Huang, HX; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Zhou, HH | 1 |
| Guo, C; Li, H; Liu, J | 1 |
| Dai, W; Ding, C; Huang, P; Huang, X; Lian, P; Ran, J; Tang, Y; Zhu, W | 1 |
| Choi, SY; Jang, S; Kim, DG; Kim, J; Kim, S; Lee, CH; Lee, KW; Lee, N; Park, JK; Suh, SB | 1 |
| Hahn, MK; Jeromson, S; McKie, GL; Medak, KD; Shamshoum, H; Wright, DC | 1 |
3 review(s) available for metformin and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Metabolic syndrome with the atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Clozapine; Humans; Metabolic Syndrome; Metformin; Obesity; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Severity of Illness Index; Weight Gain | 2010 |
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hypoglycemic Agents; Metformin; Olanzapine; Overweight; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2011 |
8 trial(s) available for metformin and olanzapine
| Article | Year |
|---|---|
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Olanzapine; Schizophrenia; Weight Gain | 2006 |
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method; Female; Fibrinogen; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Schizophrenia; Sex Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Energy Metabolism; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Male; Metformin; Middle Aged; Olanzapine; Schizophrenia; Statistics as Topic | 2007 |
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Diseases; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Prospective Studies; Schizophrenia; Sex Characteristics | 2008 |
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Olanzapine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Waist-Hip Ratio; Weight Gain | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease; Cyclobutanes; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Obesity; Olanzapine; Pilot Projects; Placebos; Schizophrenia; Schizophrenic Psychology; Waist-Hip Ratio; Weight Gain; Weight Loss | 2008 |
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Metformin; Middle Aged; Olanzapine; Psychotic Disorders; Schizophrenia; Weight Gain; Zonisamide | 2012 |
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Independent Living; Male; Mental Disorders; Metformin; Middle Aged; Olanzapine; Pilot Projects; Population Surveillance; United States; Weight Gain; Young Adult | 2016 |
21 other study(ies) available for metformin and olanzapine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Considerations regarding the use of metformin with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Metformin; Obesity; Olanzapine; Schizophrenia; Weight Loss | 2008 |
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
Topics: Antipsychotic Agents; Asian People; Benzodiazepines; Energy Intake; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Olanzapine; Schizophrenia; Triglycerides | 2008 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Energy Metabolism; Enzyme Activation; Glioblastoma; Humans; Metformin; Olanzapine; Temozolomide | 2011 |
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic Agents; Insulin Resistance; Metformin; Olanzapine; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.
Topics: Animals; Benzodiazepines; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Glyburide; Hypoglycemic Agents; Insulin; Metformin; Olanzapine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Selective Serotonin Reuptake Inhibitors; Thiazolidinediones; Time Factors | 2014 |
Metformin and berberine prevent olanzapine-induced weight gain in rats.
Topics: Adipose Tissue, White; Animals; Antipyretics; Benzodiazepines; Berberine; Eating; Female; Ion Channels; Metformin; Mitochondrial Proteins; Olanzapine; Organ Size; Rats; Rats, Sprague-Dawley; Transcriptome; Uncoupling Protein 1; Weight Gain | 2014 |
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Olanzapine; Rats; Rats, Sprague-Dawley | 2015 |
Second-generation antipsychotic and diabetes mellitus in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Blood Glucose; Clomipramine; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Lithium; Male; Metformin; Olanzapine; Valproic Acid | 2017 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female; Gene Expression Regulation; Ghrelin; Hypothalamus; Leptin; Metabolic Diseases; Metformin; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neuropeptides; Obesity; Olanzapine; RNA, Messenger; Signal Transduction; Treatment Outcome; TRPV Cation Channels | 2020 |
Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway.
Topics: Animals; Appetite Regulation; Capsaicin; Coloring Agents; Energy Metabolism; Female; Furans; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Hypothalamus; Inflammation; Metformin; Mice; Mice, Inbred BALB C; Motor Activity; Olanzapine; Ruthenium Red; Sensory System Agents; TRPV Cation Channels | 2020 |
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.
Topics: Adjuvants, Pharmaceutic; Animals; Bacteroides; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Feces; Gastrointestinal Microbiome; Humans; Lactobacillus gasseri; Liver; Male; Metabolic Diseases; Metformin; Olanzapine; Rats; RNA, Ribosomal, 16S | 2021 |
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Disease Models, Animal; Epididymis; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Olanzapine; Phenotype; Rats, Sprague-Dawley; Signal Transduction; Weight Gain | 2021 |
Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.
Topics: Animals; Liver X Receptors; Metformin; Mice; Non-alcoholic Fatty Liver Disease; Olanzapine; Proprotein Convertase 9 | 2022 |
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Hypothalamus; Leptin; Metformin; Mice; Neurons; Obesity; Olanzapine; Pro-Opiomelanocortin | 2022 |
Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose; Humans; Lipids; Metformin; Mice; Olanzapine; Salicylates; Weight Gain | 2023 |